바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.67 No.1
Citation Share

Secondary Adrenal Insufficiency Associated with Megestrol Acetate in a Patient with Lung Cancer

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2009, v.67 no.1, pp.47-51


& (2009). Secondary Adrenal Insufficiency Associated with Megestrol Acetate in a Patient with Lung Cancer. Tuberculosis & Respiratory Diseases, 67(1), 47-51.
  • Downloaded
  • Viewed
PDF Download

Abstract

Loss of appetite is an important factor in the quality of life for advanced cancer patients. Megestrol acetate is used to stimulate appetite, but it can cause suppression of the pituitary adrenal axis due to the affinity of the glucocorticoid receptor. Adrenal insufficiency is a life threatening disorder if left, untreated, but the initial clinical symptoms of the patients are vague. Awareness of the glucocorticoid-like activity of megestrol acetate and its side effects are important for the diagnosis of adrenal insufficiency. We present a case of secondary adrenal insufficiency associated with megestrol acetate in a patient with lung cancer.

keywords
Adrenal insufficiency, Lung neoplasms, Megestrol acetate

Reference

1.

Mateen F, Jatoi A. Megestrol acetate for the palliation of anorexia in advanced, incurable cancer patients. Clin Nutr 2006;25:711-5.

2.

Mann M, Koller E, Murgo A, Malozowski S, Bacsanyi J, Leinung M. Glucocorticoidlike activity of megestrol: a summary of food and drug administration experience and a review of the literature. Arch Intern Med 1997;157:1651-6.

3.

Kontula K, Paavonen T, Luukkainen T, Andersson LC. Binding of progestins to the glucocorticoid receptor: correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes. Biochem Pharmacol 1983;32:1511-8.

4.

Pascual López A, Roqué i Figuls M, Urrútia Cuchi G, Berenstein EG, Almenar Pasies B, Balcells Alegre M, et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage 2004;27:360-9.

5.

Loprinzi CL, Fonseca R, Jensen MD. Megestrol acetateinduced adrenal suppression. J Clin Oncol 1996;14:689.

6.

Ron IG, Soyfer V, Goldray D, Inbar MJ, Weisman Y. A low-dose adrenocorticotropin test reveals impaired adrenal function in cancer patients receiving megestrol acetate therapy. Eur J Cancer 2002;38:1490-4.

7.

Naing KK, Dewar JA, Leese GP. Megestrol acetate therapy and secondary adrenal suppression. Cancer 1999;86:1044-9.

8.

Chidakel AR, Zweig SB, Schlosser JR, Homel P, Schappert JW, Fleckman AM. High prevalence of adrenal suppression during acute illness in hospitalized patients receiving megestrol acetate. J Endocrinol Invest 2006;29:136-40.

9.

Raedler TJ, Jahn H, Goedeken B, Gescher DM, Kellner M, Wiedemann K. Acute effects of megestrol on the hypothalamic-pituitary-adrenal axis. Cancer Chemother Pharmacol 2003;52:482-6

10.

Salvatori R. Adrenal insufficiency. JAMA 2005;294:2481-8.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy